"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
Descriptor ID |
D015215
|
MeSH Number(s) |
D03.383.742.680.705.950 D13.570.230.500.950 D13.570.230.855.950 D13.570.685.705.950
|
Concept/Terms |
Zidovudine- Zidovudine
- Azidothymidine
- AZT Antiviral
- 3'-Azido-3'-deoxythymidine
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3'-Azido-2',3'-Dideoxythymidine
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
|
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
-
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012 May; 56(5):2305-13.